Y mAbs Therapeutics (NASDAQ:YMAB) — Stock Price
Y mAbs Therapeutics (NASDAQ:YMAB) is currently trading at $8.61 USD, up 0.23% today. Over the past 52 weeks, shares have ranged between $8.51 and $8.61. This page tracks Y mAbs Therapeutics's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of Y mAbs Therapeutics.
Y mAbs Therapeutics (YMAB) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Y mAbs Therapeutics's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Y mAbs Therapeutics Income Statement — Revenue, Profit & Earnings by Year
Y mAbs Therapeutics's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $87.69 Million | $84.82 Million | $65.27 Million | $34.90 Million | $20.75 Million |
| Cost of Revenue | $15.25 Million | $11.42 Million | $7.57 Million | $2.51 Million | $2.20 Million |
| Gross Profit | $72.43 Million | $73.40 Million | $57.70 Million | $32.38 Million | $18.55 Million |
| Research & Development | $48.99 Million | $54.22 Million | $91.57 Million | $93.25 Million | $93.70 Million |
| SG&A | $54.65 Million | $44.51 Million | $60.94 Million | $54.57 Million | $44.78 Million |
| Total Operating Expenses | $103.64 Million | $99.08 Million | $152.51 Million | $147.82 Million | $138.48 Million |
| Operating Income | $-31.20 Million | $-25.67 Million | $-94.81 Million | $-115.43 Million | $-119.94 Million |
| EBITDA | $-30.67 Million | $-24.94 Million | $-93.97 Million | $-114.65 Million | $-119.54 Million |
| EBIT | $-31.20 Million | $-25.67 Million | $-94.81 Million | $-115.43 Million | $-119.94 Million |
| Interest Expense | — | — | $757.00K | $1.85 Million | $598.00K |
| Income Before Tax | $-29.81 Million | $-20.87 Million | $-95.57 Million | $-55.27 Million | $-119.34 Million |
| Income Tax Expense | $-146.00K | $561.00K | $757.00K | $1.07 Million | $-994.00K |
| Net Income | $-29.67 Million | $-21.43 Million | $-96.33 Million | $-56.34 Million | $-119.34 Million |
Y mAbs Therapeutics Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Y mAbs Therapeutics's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $119.90 Million | $127.87 Million | $141.46 Million | $212.78 Million | $132.05 Million |
| Total Current Assets | $98.51 Million | $111.11 Million | $130.45 Million | $202.26 Million | $122.36 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | $19.69 Million | $22.45 Million | $12.53 Million | $7.71 Million | $800.00K |
| Inventory | $7.21 Million | $5.07 Million | $6.70 Million | $5.51 Million | $-800.00K |
| Property, Plant & Equipment | — | — | $2.34 Million | $5.69 Million | $1.82 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $27.90 Million | $26.88 Million | $32.23 Million | $32.68 Million | $26.21 Million |
| Total Current Liabilities | $23.70 Million | $20.13 Million | $28.28 Million | $27.88 Million | $19.54 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-66.41 Million | $-77.22 Million | $-104.00 Million | $-177.93 Million | $-110.66 Million |
| Total Stockholder Equity | $92.00 Million | $100.98 Million | $109.22 Million | $180.11 Million | $105.84 Million |
| Retained Earnings | $-487.14 Million | $-457.47 Million | $-436.04 Million | $-340.48 Million | $-285.20 Million |
Y mAbs Therapeutics Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Y mAbs Therapeutics generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-15.71 Million | $-27.23 Million | $-75.92 Million | $-102.56 Million | $-91.23 Million |
| Capital Expenditures | $0.00 | $0.00 | $0.00 | $967.00K | $175.00K |
| Free Cash Flow | $-15.71 Million | $-27.23 Million | $-75.92 Million | $-103.52 Million | $-91.41 Million |
| Investing Cash Flow | — | — | — | $61.04 Million | $-2.79 Million |
| Financing Cash Flow | $4.31 Million | $100.00K | $84.00K | $108.31 Million | $2.00 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $14.56 Million | $14.45 Million | $25.60 Million | $19.33 Million | $16.14 Million |
| Depreciation | $535.00K | $735.00K | $839.00K | $782.00K | $396.00K |
| Change in Cash | $-11.40 Million | $-27.12 Million | $-75.80 Million | $66.93 Million | $-92.50 Million |
Y mAbs Therapeutics Earnings History — EPS Actual vs. Analyst Estimates
Track Y mAbs Therapeutics's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 06, 2025 | 0.00 | -0.22 | +100.00% |
| Aug 08, 2025 | -0.07 | -0.26 | +73.08% |
| May 05, 2025 | -0.12 | -0.14 | +14.29% |
| Feb 26, 2025 | -0.15 | -0.13 | -13.64% |
| Nov 08, 2024 | -0.16 | -0.15 | -6.67% |
| Aug 12, 2024 | -0.21 | -0.13 | -61.54% |
| May 07, 2024 | -0.15 | -0.14 | -7.14% |
| Feb 29, 2024 | -0.02 | -0.20 | +90.00% |